Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.
There are multiple treatment options becoming available for diffuse large B-cell lymphoma, but more work needs to be done to understand their efficacy and in what lines of therapy they should be used.
Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.
Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.
Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, share their excitement for an upcoming program centered on the treatment paradigm of relapsed/refractory follicular lymphoma.